Home LiteratureArticle Details
PMID: 10632356 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members.

Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, Li L, Katz RL, Hung MC

Abstract

In a series of 111 patients with squamous cell carcinoma (SCC), we used immunohistochemistry to examine the expression levels of four epidermal growth factor receptor (EGFR) family members (EGFR, HER-2/neu, HER-3, and HER-4). Expression of the EGFR members was not significantly associated with tumor size. However, their expressions (except for HER-4) were significantly associated with the presence of lymph node metastasis, and all of them were significantly associated with distant metastasis. We further examined the association between the expression levels of the EGFR members and the survival rates in 47 oral SCC patients whose detailed clinical follow-ups were available. The expression of all EGFR members was significantly associated with shortened patient survival, and the association was strongest for HER-2/neu. Furthermore, the combination of HER-2, HER-3, and EGFR but not HER-4 significantly improved the predicting power. The expression level of HER-2/neu was significantly correlated with that of EGFR or HER-3. Similar coexpression patterns were also observed in three oral SCC cell lines studied, but not in four other head and neck SCC cell lines. Taken together, these results indicated that expression levels of EGFR, HER-2/ neu, and HER-3 may help predict the outcome of patients with oral SCC.

MeSH Terms
Adolescent Adult Aged Carcinoma, Squamous Cell/metabolism,mortality,pathology,therapy ErbB Receptors/biosynthesis Female Head and Neck Neoplasms/metabolism,pathology Humans Male Middle Aged Mouth Neoplasms/metabolism,mortality,pathology,therapy Predictive Value of Tests Prognosis Receptor, ErbB-2/biosynthesis Receptor, ErbB-3/biosynthesis Receptor, ErbB-4 Survival Analysis Treatment Outcome Tumor Cells, Cultured
Chemicals
ERBB4 protein, human ErbB Receptors Receptor, ErbB-2 Receptor, ErbB-3 Receptor, ErbB-4
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Xia W
Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Lau Y K
Zhang H Z
Xiao F Y
Johnston D A
Liu A R
Li L
Katz R L
Hung M C
Article Info
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Abbr.
Clin Cancer Res
ISSN
1078-0432
Published
1999-12-00
Pages
4164-74
Language
English
Region
United States
NLM ID
9502500
Subset
IM
Grants
NCI NIH HHS · CA16672 · United States
NCI NIH HHS · CA58880 · United States
NCI NIH HHS · CA60856 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]